Eli Lilly Price Forecast: The Next Big Stock After Weight-Loss Drug Breakthrough?

What Happened

The company’s stock price has benefited from this hype, gaining almost 9% in August. With Eli Lilly already valued at roughly $1.1 trillion and management recently raising its 2026 revenue guidance, investors are increasingly focused on whether future drug launches can support the premium valuation.

The investment case does not depend solely on an experimental drug. Lilly has already demonstrated that highly effective metabolic treatments can translate into enormous commercial demand.

Clinical setbacks, regulatory delays or reimbursement restrictions could therefore have an outsized effect on investor expectations.

Market Context

Eli Lilly is one of the most popular names today in America’s weight-loss and diabetes drug market. Its drugs delivered an average weight loss of 28.3% in a Phase 3 trial, approaching results historically associated with bariatric surgery and potentially giving Lilly another major product after the success of Mounjaro.

Here’s the latest Eli Lilly price prediction from CoinCodex analysts.

Earnings Growth Supports the Eli Lilly Price Prediction

The fundamental picture behind the Eli Lilly price prediction remains strong even before retatrutide reaches the market.

Those estimates represent a slowdown from Lilly’s extraordinary recent growth, with earnings having expanded at an average annual rate above 35% historically, but they still point to substantial underlying expansion for a company already carrying a market capitalization of roughly $1.1 trillion.

Why It Matters

Retatrutide Could Become Eli Lilly’s Next Major Obesity Drug

Retatrutide could therefore represent another substantial improvement in treatment effectiveness if the Phase 3 results translate into real-world use.

Retatrutide could also broaden Lilly’s opportunity beyond weight reduction alone. The report highlights results from the TRIUMPH-4 study involving participants with knee osteoarthritis, where patients receiving retatrutide experienced a substantial reduction in pain.

That creates the possibility that the drug’s commercial value could eventually extend beyond the headline obesity numbers.

Retatrutide could potentially strengthen that position by moving Lilly’s obesity portfolio from roughly 20% weight reduction toward the 30% range. The major uncertainty will be access and reimbursement.

Eli Lilly’s second-quarter 2026 revenue reached $23 billion, up 48% from the previous year, while EPS increased from $6.30 to $7.94. Revenue exceeded analyst estimates by 11%, while EPS came in 5.3% ahead of expectations.

Management has responded by repeatedly increasing its outlook. The company initially guided for $80 billion to $83 billion in 2026 revenue, raised that range to $82 billion to $85 billion in May, and lifted it again in August to between $85 billion and $87 billion.

Analysts now expect revenue to grow around 11% annually, while earnings are forecast to increase 16.6% per year and EPS approximately 16.8%. Forecast return on equity stands near 50% over the next three years.

The central risk is valuation. At that size, Lilly needs continued execution from Mounjaro, its broader drug portfolio and future products such as retatrutide to justify further appreciation.

Details

Retatrutide is emerging as one of the most important products in Eli Lilly’s development pipeline. In the Phase 3 TRIUMPH-1 study, participants taking the drug lost an average of 28.3% of their body weight after 80 weeks.

Eli Lilly executive Patrik Jönsson described the results as being in a class of their own, saying the company had not previously seen weight reduction of that magnitude.

The result is particularly significant when compared with existing obesity treatments. The report notes that patients taking Novo Nordisk’s Wegovy typically lose around 14% of their body weight after 72 weeks, while users of Lilly’s Mounjaro lose approximately 20% over a comparable period.

Eli Lilly’s Obesity Business Is Already Producing Billions

Mounjaro generated more than €27 billion in revenue during the previous 12 months, according to the attached report.

Lilly’s success in obesity treatments has helped turn the Indianapolis-based company into the world’s most valuable pharmaceutical group, with its valuation around five times that of Novo Nordisk and more than four times that of AstraZeneca at the time of the report.

That performance followed an exceptionally strong first quarter, when revenue climbed 56% year over year to $19.8 billion and net income jumped 168% to $7.4 billion. Full-year 2025 revenue had already increased 45% to $65.2 billion, illustrating how quickly Lilly’s existing product portfolio has expanded.